These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21573168)

  • 1. In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.
    Ullrich RT; Jikeli JF; Diedenhofen M; Böhm-Sturm P; Unruh M; Vollmar S; Hoehn M
    PLoS One; 2011 May; 6(5):e19592. PubMed ID: 21573168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
    Righi M; Giacomini A; Lavazza C; Sia D; Carlo-Stella C; Gianni AM
    Lab Invest; 2009 Sep; 89(9):1063-70. PubMed ID: 19652644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
    Turetschek K; Preda A; Floyd E; Shames DM; Novikov V; Roberts TP; Wood JM; Fu Y; Carter WO; Brasch RC
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):448-55. PubMed ID: 12722742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization.
    Matsumoto S; Saito K; Takakusagi Y; Matsuo M; Munasinghe JP; Morris HD; Lizak MJ; Merkle H; Yasukawa K; Devasahayam N; Suburamanian S; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2014 Sep; 21(8):1145-55. PubMed ID: 24597714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
    Zhang YH; Yue ZJ; Zhang H; Tang GS; Wang Y; Liu JM
    Eur J Pharm Biopharm; 2010 Nov; 76(3):371-5. PubMed ID: 20816959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of PTK/ZK on the angiogenic switch in head and neck tumors.
    Miyazawa M; Dong Z; Zhang Z; Neiva KG; Cordeiro MM; Oliveira DT; Nör JE
    J Dent Res; 2008 Dec; 87(12):1166-71. PubMed ID: 19029087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.
    Bhattacharya A; Turowski SG; San Martin ID; Rajput A; Rustum YM; Hoffman RM; Seshadri M
    Anticancer Res; 2011 Feb; 31(2):387-93. PubMed ID: 21378316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry.
    Sottnik JL; Guth AM; Mitchell LA; Dow SW
    Angiogenesis; 2010 Sep; 13(3):251-8. PubMed ID: 20734228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
    Ravoori MK; Nishimura M; Singh SP; Lu C; Han L; Hobbs BP; Pradeep S; Choi HJ; Bankson JA; Sood AK; Kundra V
    PLoS One; 2015; 10(6):e0131095. PubMed ID: 26098849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
    Lemasson B; Christen T; Tizon X; Farion R; Fondraz N; Provent P; Segebarth C; Barbier EL; Genne P; Duchamp O; Remy C
    NMR Biomed; 2011 Jun; 24(5):473-82. PubMed ID: 21674650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.
    Awazu Y; Mizutani A; Nagase Y; Tsuchiya S; Nakamura K; Kakoi Y; Kitahara O; Takeuchi T; Yamasaki S; Miyamoto N; Iwata H; Miki H; Imamura S; Hori A
    Cancer Sci; 2013 Apr; 104(4):486-94. PubMed ID: 23305239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation.
    Hlushchuk R; Riesterer O; Baum O; Wood J; Gruber G; Pruschy M; Djonov V
    Am J Pathol; 2008 Oct; 173(4):1173-85. PubMed ID: 18787105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo.
    Chao WR; Amin K; Shi Y; Hobbs P; Tanabe M; Tanga M; Jong L; Collins N; Peters R; Laderoute K; Dinh D; Yean D; Hou C; Sato B; Alt C; Sambucetti L
    Angiogenesis; 2011 Mar; 14(1):1-16. PubMed ID: 21104121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.